BioMarin Pharmaceutical - BMRN Stock Forecast, Price & News

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Barclays increased their target price on BioMarin Pharmaceutical from $112.00 to $125.00 and gave the company an "overweight" rating in a report on Thursday, August 4th. Piper Sandler increased their target price on BioMarin Pharmaceutical from $125.00 to $128.00 and gave the company an "overweight" rating in a report on Tuesday. Robert W. Baird restated an "outperform" rating and issued a $112.00 price target on shares of BioMarin Pharmaceutical in a research report on Tuesday, June 28th. StockNews.com upgraded BioMarin Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Tuesday. Finally, Cantor Fitzgerald began coverage on BioMarin Pharmaceutical in a research report on Tuesday, July 12th. They issued an "overweight" rating and a $110.00 price target for the company. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, BioMarin Pharmaceutical has an average rating of "Moderate Buy" and an average price target of $110.93.

BioMarin Pharmaceutical Stock Performance

Shares of NASDAQ:BMRN remained flat at $95.70 during midday trading on Tuesday. The company had a trading volume of 1,099,413 shares, compared to its average volume of 1,245,382. The company has a current ratio of 5.42, a quick ratio of 3.69 and a debt-to-equity ratio of 0.24. BioMarin Pharmaceutical has a 52-week low of $70.73 and a 52-week high of $97.76. The company's 50-day moving average is $83.51 and its two-hundred day moving average is $82.34. The company has a market capitalization of $17.75 billion, a PE ratio of 368.09, a P/E/G ratio of 1.97 and a beta of 0.33.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Rating) last released its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.04. BioMarin Pharmaceutical had a return on equity of 1.78% and a net margin of 2.83%. During the same quarter last year, the company earned $0.23 EPS. As a group, analysts forecast that BioMarin Pharmaceutical will post 0.98 earnings per share for the current year.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 7,398 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Friday, July 8th. The stock was sold at an average price of $90.00, for a total value of $665,820.00. Following the sale, the executive vice president now owns 58,941 shares of the company's stock, valued at approximately $5,304,690. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other BioMarin Pharmaceutical news, EVP Jeffrey Robert Ajer sold 1,308 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $78.94, for a total value of $103,253.52. Following the sale, the executive vice president now owns 54,109 shares of the company's stock, valued at approximately $4,271,364.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP George Eric Davis sold 7,398 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Friday, July 8th. The shares were sold at an average price of $90.00, for a total transaction of $665,820.00. Following the sale, the executive vice president now owns 58,941 shares of the company's stock, valued at $5,304,690. The disclosure for this sale can be found here. Insiders have sold a total of 16,043 shares of company stock valued at $1,425,735 over the last quarter. 1.75% of the stock is currently owned by insiders.